Why Is Cancer Immunotherapy Focused Evaxion Biotech Stock Trading Higher Today?
Portfolio Pulse from Vandana Singh
Evaxion Biotech (NASDAQ:EVAX) has partnered with Afrigen Biologics to develop a prophylactic vaccine based on Evaxion's EDEN-discovered gonorrhea targets. The partnership aims to address a serious global medical need as there is currently no vaccine for gonorrhea. The EDEN-discovered antigens have shown high levels of protection in preclinical studies. The partners will negotiate a subsequent agreement for clinical development and commercialization after the validation phase. Evaxion Biotech also initiated a new pipeline program, EVX-B3, in collaboration with an undisclosed pharmaceutical company.

September 20, 2023 | 5:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evaxion Biotech's partnership with Afrigen Biologics to develop a gonorrhea vaccine and the initiation of a new pipeline program could potentially boost the company's stock in the short term.
The partnership with Afrigen Biologics to develop a vaccine for a disease with no existing vaccine could potentially increase Evaxion Biotech's market value. Additionally, the initiation of a new pipeline program, EVX-B3, could also contribute to the company's growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100